Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.8. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||101%|
|1 Day Vol Adjusted Return||0.3|
|1 Month Vol Adjusted Return||-1.5|
|3 Month Vol Adjusted Return||-2.8|
|6 Month Vol Adjusted Return||3.1|
|20 Days SMA Price ZScore||1.2|
|50 Days SMA Price ZScore||-0.0|
|12 -26 Days PPO||-2.0|
|1 Month Average Short Volume Ratio||33.7|
|1 Day Volume Change ZScore||-0.7|
|1 Month Daily Vol||5.4|
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT (3:00 p.m. ET).
A pair of biotechnology companies with offices on the Peninsula are cutting a combined 163 employees. Natera Inc. alerted state employment officials of its layoffs Nov. 4, the same day it notified 58 of its San Carlos-based workers that they were losing their jobs. Synthego Corp., meanwhile, alerted state authorities on Nov. 14 that it planned to cut 105 employees in Redwood City last Friday.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which shows that its mPCR technology is able to assess response to tebentafusp in treatment-refractory metastatic uveal melanoma. The findings indicated an association between early reductions in ctDNA and longer overall survival, suggesting that traditional radiographic-based response criteria don't accurately reflect tebentafusp-related clinical activity and
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 2022, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,714,500 shares of its common stock at the public offering price
Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $52,500,000 of shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assura
Natera ( NASDAQ:NTRA ) Third Quarter 2022 Results Key Financial Results Revenue: US$210.6m (up 33% from 3Q 2021). Net...
Natera (NTRA) delivered earnings and revenue surprises of 11.97% and 1.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022.
Alger Capital, an investment management company, released its “Alger Spectra Fund” third quarter investor letter. A copy of the same can be downloaded here. In the third quarter, Class A shares of the fund outperformed the Russell 3000 Growth Index. In the quarter, the portfolio’s largest sector overweight was Health Care, and the largest sector underweight […]
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was awarded a nationwide contract, effective Sept. 15, 2022, with the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program, to provide minimal residual disease (MRD) and monitoring services with the company's personalized and tumor-informed MRD test, Signatera™.